Nature and Science of Sleep

We are pleased to announce a new Article Collection in Nature and Science of Sleep, dedicated to the game-changing role of Continuous Positive Airway Pressure (CPAP) therapy in the management of obstructive sleep apnea (OSA). Since its clinical introduction, CPAP therapy has revolutionized patient care, offering significant benefits in improving sleep quality, reducing daytime fatigue, and enhancing overall cardiovascular health for eligible patients.

Given the importance of CPAP therapy in managing obstructive sleep apnea, Nature and Science of Sleep invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies.

The Collection, edited by Editor-In-Chief Professor Ahmed BaHammam, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.

While the call is open to receive manuscripts across the broad spectrum of CPAP therapy in obstructive sleep apnea, the Editors are particularly interested in manuscripts relating to the following areas:
• Pathophysiological mechanisms of CPAP and alleviation of OSA symptoms
• Randomized controlled trials assessing the clinical effectiveness of CPAP therapy in OSA
• Observational studies examining the relationship between CPAP use and outcomes in the real-world setting.
• Studies focused on CPAP adherence and patient adherence
• Personalized CPAP approaches - Given the growing recognition that OSA treatment needs individualization beyond the traditional "one-size-fits-all" approach.
• Technology integration and telemedicine - The role of remote monitoring, mobile health applications, and digital therapeutics in improving CPAP adherence.
• Health economics and accessibility - Studies examining cost-effectiveness and strategies to improve access, particularly in developing countries where simpler, lower-cost CPAP devices show promise.
• Cardiovascular outcomes research - More robust studies addressing the ongoing debate about CPAP's cardiovascular benefits, particularly focusing on adherent patients.

Submitting authors will be eligible for a 20% discount on the Article Publishing charge by entering the code B2707. The code must be applied at the point of submission.

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

Please review the journal's Aims and Scope and author submission instructions prior to submitting a manuscript. Please submit your manuscript through the Dovepress website. The manuscript submission deadline is 1 April 2026.

If you have any queries regarding the Article Collection or would like to discuss a submission, please email the Commissioning Editor at [email protected].

View all papers in this article collection

We are pleased to announce a new Article Collection in Nature and Science of Sleep, focused on the role of orexin receptor antagonists in the management of insomnia.

Where behavioral interventions are not effective, pharmacological treatments can offer an alternative for insomnia patients. However, while benzodiazepines and "Z-drugs" can be effective in the short term, long-term use is associated with side effects including the development of tolerance and addiction. Orexin receptor antagonists, a relatively new class of medications, have reduced dependance and tolerance-inducing effects, showing promise for longer-term use.

Given the emerging importance of orexin receptor antagonists in managing insomnia, Nature and Science of Sleep invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these therapies.

The Collection, edited by the Editor-In-Chief Professor Ahmed BaHammam, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies and drugs.

While the call is open to receive manuscripts across the broad spectrum of orexin receptor antagonists in insomnia, the Editors are particularly interested in manuscripts relating to the following areas:
• Studies exploring the neurobiological pathways and mechanisms through which orexin receptor antagonists exert their effects.
• Studies evaluating the efficacy of orexin receptor antagonists in different patient populations.
• Studies assessing the safety and tolerability of orexin receptor antagonists.
• Comorbid conditions - Studies examining orexin antagonists in patients with insomnia and concurrent sleep disorders or psychiatric conditions.
• Comparative effectiveness research - Head-to-head studies with other insomnia treatments.
• Long-term safety profiles - Extended follow-up studies given the relatively recent introduction of these medications.

Submitting authors will be eligible for a 20% discount on the Article Publishing charge by entering the code 20F21. The code must be applied at the point of submission.

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

Please review the journal's Aims and Scope and author submission instructions prior to submitting a manuscript. Please submit your manuscript through the Dovepress website. The manuscript submission deadline is 1 April 2026.

If you have any queries regarding the Article Collection or would like to discuss a submission, please email the Commissioning Editor at [email protected].

View all papers in this article collection